Skip to content
Friday, November 13, 2026
Scotia Arena UK

Individuals Coming Off Anti-Obesity Medications Gain Back Pounds Four Times Faster Compared to People Using Diet and Exercise

Illustration of pharmaceutical syringe and weighing machine
Weight management involves long-term strategies.

New research indicates that patients who discontinue new GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight much more quickly than those who stop conventional diet and exercise plans.

Published data in a prominent health publication demonstrates that while overweight individuals can lose a large proportion of their body weight while undergoing treatment, the weight returns at an average rate of 0.8 kg per month once they quit.

"People purchasing these treatments need to be informed of the danger of fast rebound weight gain when the therapy concludes," cautioned researcher Dr. Susan Jebb.

This pace of recovery implies a return to starting weight in about one and a half years.

Analyzing Therapies

The research, which looked at 37 of studies involving over 9,000 of participants, compared the results of these new drugs with older methods.

The team point out that people who shed pounds through diet and exercise usually see a slower weight regain—around 100 grams monthly—post-intervention.

Explaining the Fast Regain

Doctors suggest the mode of action of the injections explains the accelerated rebound.

The injections imitate a natural hormone called GLP-1, which helps regulate hunger.

"Sustained high doses of GLP-1 levels far above than the body's typical production might result in the system to generate a reduced amount of its endogenous hormone, and could lessen sensitivity to its effects," said Dr. Adam Collins, a nutrition researcher.

"Discontinuation of this medication results in hunger is uncontrolled, making overeating much more probable."

A Lifelong Disease?

Medical guidelines recommend the jabs for people with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.

Professionals argue that, considering the high risk of weight regain, the therapy should be considered ongoing.

This opinion is echoed by pharmaceutical companies, who note that the findings "underscore the long-term nature of excess weight," comparing it to managing conditions like high blood pressure.

User Testimonies

Individuals who have discontinued the medication report a intense resurgence of appetite.

"I experienced a trigger that goes on and I was suddenly ravenous," said one woman.

This difficulty is worsened if users have not established lasting lifestyle or habit changes during treatment.

Widespread Use

Recent estimates show that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with desire continuing to grow.

  • Adoption is higher among women compared to men.
  • The 40s and 50s demographic shows the greatest usage rates.
  • A large proportion obtain the medications through private healthcare rather than public health services.

Ultimately, researchers stress that while GLP-1 drugs are potent tools for shedding pounds, they are not a permanent fix and lasting health benefits relies on combined lifestyle changes.

JS
About the author

John Stone

Elena is a sports journalist and event coordinator with over a decade of experience covering UK venues and entertainment.

Scotia Arena UK

Type to search articles.